LEO Pharma Overview
Pro stress-test →LEO Pharma is a manufacturer of medicines for treating skin diseases based in Ballerup, Denmark. A global leader in medical dermatology, the company delivers innovative solutions for skin health on a century of experience, with a broad portfolio of treatments serving close to 100 million patients in over 70 countries annually. The company is executing a strategic transformation with strong momentum in rare and medical dermatology.
Strategic Profile
Pro stress-test →LEO Pharma's dermatology portfolio is growing through strategic brands Adtralza®/Adbry®, Anzupgo®, and Spevigo®, which combined had a revenue increase of 48% in 2025. The company is advancing innovation through partnerships and acquisitions, including the acquisition of Replay's gene therapy platform for rare genetic skin diseases in April 2026. LEO Pharma is co-owned by majority shareholder the LEO Foundation and Nordic Capital since 2021.
Competitive Landscape
Pro stress-test →LEO Pharma focuses on medical dermatology with therapies for psoriasis, eczema, acne, and infections, alongside anticoagulant treatments for cancer patients. Key competitors in dermatology include Stiefel Laboratories (GSK), Abbvie's Allergan, Novartis Dermatology, and Boehringer Ingelheim's dermatology business. Within rare dermatology and emerging therapies, LEO competes with Jazz Pharmaceuticals, Roivant Sciences, and Amgen.
Industry Context
LEO Pharma operates in Pharmaceutical - Dermatology.
Key facts
Founded: 1908 · Headquarters: Ballerup, Denmark · Employees: 4,300 · Revenue: 13.5B DKK (2025)